Drugs / HS248
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05759234 | Nov 2022 → Oct 2023 | cancer | Hanhui Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS248 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05759234 ↗ |
| Action | Inhibit | “PI3Kγ inhibitor” NCT05759234 ↗ |